Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT

por Kairemo, Kalevi, Joensuu, Timo
Publicado 2015

Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients

por Kairemo, Kalevi, Rasulova, Nigora, Partanen, Kaarina, Joensuu, Timo
Publicado 2014

The Clip Approach: A Visual Methodology to Support the (Re)Construction of Life Narratives

por Talsi, Riikka, Laitila, Aarno, Joensuu, Timo, Saarinen, Esa
Publicado 2021

A Retrospective Comparative Study of Sodium Fluoride (NaF-18)-PET/CT and Fluorocholine (F-18-CH) PET/CT in the Evaluation of Skeletal Metastases in Metastatic Prostate Cancer Using...

por Kairemo, Kalevi, Kappadath, S. Cheenu, Joensuu, Timo, Macapinlac, Homer A.
Publicado 2020

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics

por Kairemo, Kalevi, Joensuu, Timo, Rasulova, Nigora, Kiljunen, Timo, Kangasmäki, Aki
Publicado 2015

A Retrospective Comparative Study of Sodium Fluoride Na(18)F-PET/CT and (68)Ga-PSMA-11 PET/CT in the Bone Metastases of Prostate Cancer Using a Volumetric 3-D Radiomic Analysis

por Kairemo, Kalevi, Kangasmäki, Aki, Kappadath, Srinivasan Cheenu, Joensuu, Timo, Macapinlac, Homer A.
Publicado 2022

(177)Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer

por von Eyben, Finn E., Kiljunen, Timo, Joensuu, Timo, Kairemo, Kalevi, Uprimny, Christian, Virgolini, Irene
Publicado 2017

Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

por von Eyben, Finn Edler, Roviello, Giandomenico, Kiljunen, Timo, Uprimny, Christian, Virgolini, Irene, Kairemo, Kalevi, Joensuu, Timo
Publicado 2017

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy

por Hemminki, Otto, Oksanen, Minna, Taipale, Kristian, Liikanen, Ilkka, Koski, Anniina, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Publicado 2018

Single Center Experience with a 4-Week (177)Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer

por Kemppainen, Jukka, Kangasmäki, Aki, Malaspina, Simona, Pape, Bernd, Jalomäki, Jarno, Kairemo, Kalevi, Kononen, Juha, Joensuu, Timo
Publicado 2022

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment

por Hirvinen, Mari, Heiskanen, Raita, Oksanen, Minna, Pesonen, Saila, Liikanen, Ilkka, Joensuu, Timo, Kanerva, Anna, Cerullo, Vincenzo, Hemminki, Akseli
Publicado 2013

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy

por Liikanen, Ilkka, Koski, Anniina, Merisalo-Soikkeli, Maiju, Hemminki, Otto, Oksanen, Minna, Kairemo, Kalevi, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Publicado 2015

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients

por Taipale, Kristian, Tähtinen, Siri, Havunen, Riikka, Koski, Anniina, Liikanen, Ilkka, Pakarinen, Päivi, Koivisto-Korander, Riitta, Kankainen, Matti, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Publicado 2018

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer

por Liikanen, Ilkka, Basnet, Saru, Quixabeira, Dafne C A, Taipale, Kristian, Hemminki, Otto, Oksanen, Minna, Kankainen, Matti, Juhila, Juuso, Kanerva, Anna, Joensuu, Timo, Tähtinen, Siri, Hemminki, Akseli
Publicado 2022

(177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer

por von Eyben, Finn Edler, Singh, Aviral, Zhang, Jingjing, Nipsch, Karin, Meyrick, Danielle, Lenzo, Nat, Kairemo, Kalevi, Joensuu, Timo, Virgolini, Irene, Soydal, Cigdem, Kulkarni, Harshad R., Baum, Richard Paul
Publicado 2019

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

por Hemminki, Otto, Parviainen, Suvi, Juhila, Juuso, Turkki, Riku, Linder, Nina, Lundin, Johan, Kankainen, Matti, Ristimäki, Ari, Koski, Anniina, Liikanen, Ilkka, Oksanen, Minna, Nettelbeck, Dirk M., Kairemo, Kalevi, Partanen, Kaarina, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli
Publicado 2015

Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival

por Pesonen, Sari, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Joensuu, Timo, Kairemo, Kalevi, Partanen, Kaarina, Alanko, Tuomo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Hemminki, Akseli, Backman, Charlotta, von Euler, Mikael, Hakonen, Tiina, Ranki, Tuuli, Vuolanto, Antti, Jäderberg, Magnus, Zamarin, Dmitry
Publicado 2015

Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients

por Majumder, Mamun, Kumar, Ashwini, Heckman, Caroline, Kankainen, Matti, Pesonen, Sari, Jäger , Elke, Karbach , Julia, Joensuu, Timo, Kairemo, Kalevi, Partanen, Kaarina, Alanko, Tuomo, Hemminki, Akseli, Backman, Charlotta, Dienel, Kasper, von Euler, Mikael, Hakonen, Tiina, Juhila, Juuso, Ranki, Tuuli, Vassilev, Lotta, Vuolanto, Antti, Jaderberg, Magnus
Publicado 2014

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polari...

por Ranki, Tuuli, Joensuu, Timo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kairemo, Kalevi, Alanko, Tuomo, Partanen, Kaarina, Turkki, Riku, Linder, Nina, Lundin, Johan, Ristimäki, Ari, Kankainen, Matti, Hemminki, Akseli, Backman, Charlotta, Dienel, Kasper, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Juhila, Juuso, Jaderberg, Magnus, Priha, Petri, Vassilev, Lotta, Vuolanto, Antti, Pesonen, Sari
Publicado 2014

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

por Ranki, Tuuli, Pesonen, Sari, Hemminki, Akseli, Partanen, Kaarina, Kairemo, Kalevi, Alanko, Tuomo, Lundin, Johan, Linder, Nina, Turkki, Riku, Ristimäki, Ari, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kankainen, Matti, Backman, Charlotta, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Heiskanen, Raita, Jaderberg, Magnus, Juhila, Juuso, Priha, Petri, Suoranta, Laura, Vassilev, Lotta, Vuolanto, Antti, Joensuu, Timo
Publicado 2016